ClinicalTrials.gg
RecruitingNCT07899073Updated Oct 27, 2026

A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients

A Phase 3 interventional study of HIP2602 + HPP2602-2 and HPP2602-1 + HPP2602-2 in Erectile Dysfunction, sponsored by Hanmi Pharmaceutical Company Limited. Recruiting at 1 site in South Korea. Open to male participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

Updated Oct 27, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies in Erectile Dysfunction with a site in Korea, Republic of — 3 open to participants now, 3 under way, 2 of them phase 3. Erectile Dysfunction · Korea, Republic of.

Planned enrollment
5th of 25
225 · median 104
Started
2026
with 1 other
Phase 3
8 of 31
2 open now
Registered
31st of 31
by date
Lead sponsor
4 of 31
Hanmi Pharmaceutical Company Limited

Among the 31 studies in Erectile Dysfunction with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 in phase 3, and was the 31st registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

3 of the 31 studies in Erectile Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 19 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Erectile Dysfunction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Visit 1 (screening)

  • Male subjects aged 19 to 75 years, inclusive.
  • Subjects with a history of erectile dysfunction for at least 3 months prior to Visit 1.
  • Subjects who are expected to have sexual intercourse with the same adult female partner throughout the study period.
  • Subjects who agree to attempt sexual intercourse at least 4 times on 4 separate days during the run-in period.

Visit 2 (Randomization)

  • Subjects with an International Index of Erectile Function (IIEF) Erectile Function (EF) domain score of ≤25 at Visit 2.
  • Subjects who attempted sexual intercourse at least 4 times on 4 separate days during the run-in period and demonstrated a sexual intercourse failure rate of ≥50%, as assessed by the Sexual Encounter Profile (SEP).

Exclusion criteria

Exclusion Criteria:

  • Erectile dysfunction associated with premature ejaculation or endocrine disorders (e.g., hypogonadism, hyperprolactinemia, thyroid disorders)
  • Uncontrolled diabetes mellitus ( > 10% at Visit 1)
  • History of radical prostatectomy or other pelvic surgery
  • Presence of anatomical penile deformity (e.g., Peyronie's disease, penile angulation, cavernosal fibrosis)
  • History of major cardiovascular or cerebrovascular disease, including unstable angina, recent myocardial infarction, stroke, uncontrolled arrhythmia, or heart failure
  • History of retinitis pigmentosa, NAION, or other hereditary retinal degenerative disorders
  • hepatic or renal impairment
  • Positive serology for infectious diseases at Visit 1
  • Prior failure to respond to PDE-5 inhibitor therapy
  • Use of prohibited concomitant medications or anticipated need for such medications during the study
  • Participation in another clinical trial within 30 days prior to Visit 1
  • Known to the study drug or its components
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    HIP2602 + HPP2602-2

    Daily administration, oral

    Drug: HIP2602 + HPP2602-2

  • Placebo comparator
    HPP2602-1 + HPP2602-2

    Daily administration, oral

    Drug: HPP2602-1 + HPP2602-2

  • Other
    HGP1201 + HPP2602-1

    Daily administration, oral

    Drug: HGP1201 + HPP2602-1

Interventions

  • DrugHIP2602 + HPP2602-2

    Test drug

  • DrugHPP2602-1 + HPP2602-2

    Control drug

  • DrugHGP1201 + HPP2602-1

    Active Comparator

06

What researchers measure

Primary outcomes

  1. Change of IIEF-EF domain score from baseline after 12 weeks

    Time frame: baseline, 12 weeks

Secondary outcomes

  1. Change of IIEF-EF domain score from baseline after 6 weeks

    Time frame: baseline, 6 weeks

  2. Change of IIEF-OF domain score from baseline after 6, 12 weeks

    Time frame: baseline, 6 weeks, 12 weeks

  3. Change of IIEF-SD domain score from baseline after 6, 12 weeks

    Time frame: baseline, 6 weeks, 12 weeks

  4. Change of IIEF-IS domain score from baseline after 6, 12 weeks

    Time frame: baseline, 6 weeks, 12 weeks

  5. Change of IIEF-OS domain score from baseline after 6, 12 weeks

    Time frame: baseline, 6 weeks, 12 weeks

  6. Change of IIEF Question 3 score from baseline after 6, 12 weeks

    Time frame: baseline, 6 weeks, 12 weeks

  7. Change of IIEF Question 4 score from baseline after 6, 12 weeks

    Time frame: baseline, 6 weeks, 12 weeks

  8. The proportion or participants achieving IIEF-EF domain score ≥ 26 after 6, 12 weeks

    Time frame: 6 weeks, 12 weeks

  9. The proportion (%) of participants who responded "Yes" to Sexual Encounter Profile (SEP) Questions 1, 2, 3, 4, and 5 at Weeks 6 and 12 compared with baseline

    Time frame: baseline, 6 weeks, 12 weeks

  10. The proportion of participants who responded "Yes" to Global Assessment Question (GAQ) at Week 12

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.

Of 16 phase 3 interventional studies under Erectile Dysfunction, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2026
First posted
Oct 27, 2026
StartEst.
Oct 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07899073
Responsible party
Sponsor
First posted
Oct 27, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Jee Won Shon
Contact
jeewon.shon@hanmi.co.kr
82-2-410-9037
Hyun Jun Park
Contact
joon501@naver.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion